Clinical trial

Study of ORIC-101 in Combination With Enzalutamide

NCT04033328

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-10-28

PhasePHASE1

Study timeline

Study start (actual)2019-10-28Date precision: day

Registry last updated2023-12-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostatic Neoplasmsunresolved

Interventions

ORIC-101DRUG

enzalutamide 40 MG oral capsule [Xtandi]DRUG · verified · RxNorm: enzalutamide 40 MG Oral Capsule [Xtandi]

Sponsors & collaborators

ORIC Pharmaceuticalslead sponsor

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04033328 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.